Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Inclusion Criteria: * Signed informed consent form * Ability and willingness to comply with the requirements of the study protocol * Histologic diagnosis of mantle cell lymphoma. This diagnosis must be confirmed at the treating center and patients must have this diagnosis confirmed by at least one of the following criteria: * Fluorescent in situ hybridization (FISH) or conventional cytogenetics positive for t(11;14) * Cyclin D1 positive by immunohistochemistry * Documentation by a hematopathologist at the treating institution that there is pathologic evidence of mantle cell lymphoma if neither criteria above are met * No previous therapy for diagnosis of lymphoma (note that in patients deemed to be high-risk for tumor lysis syndrome or for rapid clinical deterioration due to symptomatic disease by the investigator, a short course of steroids designed to decrease tumor burden is permitted) * Eastern Cooperative Oncology Group performance status of 0, 1, or 2 * Hemoglobin ≥ 9 g/dL * Absolute neutrophil count ≥ 1.5 x 10⁹/L * Platelet count ≥ 75 x 10⁹/L * Serum creatinine ≤ 2.0 mg/dL or creatinine clearance ≥ 40 mL/min * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) * Total bilirubin \< 1.5 x ULN (or ≤ 3 x ULN for patients with documented Gilbert syndrome) * NOTE: Patients with renal or hepatic impairment that is disease-related (ie, hydronephrosis, hepatic involvement) in the opinion of the investigator but who …